Member Info for Breq

From the 2015 Admission Document the CRO is Gaea Clinical, a small - one man band? - CRO set up in 2014. Seems a strange choice for a public company about to spend over ten million on a phase 3 clinical trial to use a small, newly incorporated outfit for a 60 hospital trial in 8 countries. Maybe only Gaea had the expertise? A big CRO would have been as capable?

8 May placebo results also fit the 6 batch theory. 14.6 plus 14.6 plus 32.3 gives average mortality of 20.5, so close to the unusually low 23% reported. Only the figures support this. Could just be a statistical quirk but just maybe.

The 6 batch theory fits about exactly. From 14 June RNS Traumakine when shown to be taken by the patients (biomarkers) results in 14.6% mortality. When not shown in patients mortality is 32.3% as expected. From 8 May trial results mortality was 26.4% in Traumakine treated patients. Very high. But if only one third were given Traumakine and two thirds placebo then take 14.6 plus 32.3 plus 32.3 and divide by 3 you get an average mortality of ... drum roll .... 26.4. Could be. Could be. Really hope they can link the batches to individual patients.

If they could trace which batch was used on which patients and could show a batch screw up then the data might actually show that Traumakine worked as expected and real placebo mortality was 32% as expected. Can't believe this could happen but it would fit in with the reported figures. Super unusually low placebo mortality and traumakine working as expected in exactly one third of 'treated' patients. Couldn't be surely.

Super weird. June 14 RNS gives Traumakine working as expected in 48 patients but not in the other 96 patients treated. Does that mean 3 batches of drugs were used and only one batch was the right formulation/stored right ? Or, Mortality in the other 96 patients was exactly as expected as if on placebo at 32%. The placebo arm mortality was actually 23%. Only way you could easily explain these figures is if they gave 1 batch of Traumakine to treated patients and 2 batches of placebo to treated patients. Placebo patients got 2 batches of Traumakine and 1 batch of placebo. Did they use a CRO for the trial or do it themselves ? Must have used a CRO. They've never named the CRO. Have taken modest position on this being an all time batch screw up.

Modest but good buying interest at 45p and 46p. Sellers seem to have finished for now. Would be good to hear an update on the big pilot trials Albert's running. Any of which would be transformational for revenue. Maybe the AGM later this month will include an update.

Share price appreciation is 'proceeding according to plan. I anticipate' further market 'penetration' and company 'acquisition' targets. If anyone doubts that then 'f__k off'.

Primary endpoint on MBC trial is 'Determine the proportion of MBC patients and healthy volunteers (HVs or controls) that have one or more observable CTCs (as determined by a qualified pathologist using cytological evaluation of Wright-Giemsa stained slides) harvested from their peripheral blood using the Parsortix PC1 system.' Low hurdle. Zero on truly healthy volunteers. Parsortix picked up CTCs in all MBC sufferers in recent posters and publications. Current stock buying in anticipation of low hurdle primary endpoint being conclusively met at mid year result read out ?